TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Mar 31, 2026. Filed Apr 29, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 29, 2026

TEVA$42.97+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(U.S. dollars in millions, except for share data)

	March 31,2026	December 31,2025
ASSETS
Current assets:
Cash and cash equivalents	$3,741	$3,556
Accounts receivables, net of allowance for credit losses of $75 million and $81 million as of March 31, 2026 and December 31, 2025, respectively.	3,393	3,709
Inventories	3,176	3,179
Prepaid expenses	1,070	1,122
Other current assets	535	539
Assets held for sale	1,794	1,842
Total current assets	13,710	13,946
Deferred income taxes	2,190	2,191
Other non-current assets	377	405
Property, plant and equipment, net	3,998	4,080
Operating lease right-of-use assets, net	335	345
Identifiable intangible assets, net	3,609	3,781
Goodwill	15,822	16,000
Total assets	$40,040	$40,748
LIABILITIES AND EQUITY
Current liabilities:
Short-term debt	$2,612	$1,820
Sales reserves and allowances	3,707	4,143
Accounts payables	2,596	2,531
Employee-related obligations	555	739
Accrued expenses	2,616	2,687
Other current liabilities	1,111	1,182
Liabilities held for sale	334	354
Total current liabilities	13,532	13,456
Long-term liabilities:
Deferred income taxes	273	296
Other taxes and long-term liabilities	3,709	3,808
Senior notes and loans	14,015	14,986
Operating lease liabilities	280	288
Total long-term liabilities	18,277	19,379
Total liabilities	31,809	32,834
Equity:
Teva shareholders’ equity:
Ordinary shares of NIS 0.10 par value per share; March 31, 2026 and December 31, 2025: authorized 2,495 million shares; issued 1,271 million shares and 1,257 million shares, respectively.	59	58
Additional paid-in capital	28,203	28,133
Accumulated deficit	(13,394)	(13,762)
Accumulated other comprehensive loss	(2,512)	(2,391)
Treasury shares as of March 31, 2026 and December 31, 2025: 107 million ordinary shares.	(4,128)	(4,128)
	8,228	7,910
Non-controlling interests	4	4
Total equity	8,232	7,914
Total liabilities and equity	$40,040	$40,748

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.